Efficacy and Durability: New Therapies vs Aflibercept 2mg


Experts reflect on the current information available on the safety and durability of second-generation agents aflibercept 8 mg and faricimab.


In this segment, the discussion centers on the efficacy and durability of different anti-VEGF agents, specifically aflibercept 2 mg, 8 mg, and faricimab. Diana Do, MD emphasizes the challenges in making direct head-to-head comparisons between these agents, as they were not tested against each other in clinical trials with the same design. The focus shifts particularly to durability gains between therapies, highlighting the need for new clinical trials designed for such comparisons. Experts agree that increased durability while maintaining vision anatomy and perception is the gold standard of care for retinal disease therapies.

David Eichenbaum, MD raises a question about the drying efficacy of aflibercept 8 milligrams compared to aflibercept 2 mg in wet AMD. Seenu Hariprasad, MD responds, stating that there is good level-one evidence demonstrating that the second-generation agents, including aflibercept 8 mg, exhibit superior drying effects compared to the older generation agents like aflibercept 2 mg. He notes an increase in drying effect with the new generation agents and emphasizes the importance of drying in controlling vision outcomes.

This summary was AI-generated and edited for clarity.

Related Videos
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
© 2024 MJH Life Sciences

All rights reserved.